5.19
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Cellectar Biosciences Inc. Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia
What institutions are buying Cellectar Biosciences Inc. stock nowFree Stock Market Return Analysis - jammulinksnews.com
What drives Cellectar Biosciences Inc. stock priceMassive wealth growth - Autocar Professional
Is Cellectar Biosciences Inc. a good long term investmentSuperior stock selection - Autocar Professional
What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional
Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
How Cellectar Biosciences Inc. stock performs during market volatilityRapid Gain Targets - Newser
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Insider Buying: James Caruso Acquires 10,000 Shares of Cellectar Biosciences Inc (CLRB) - GuruFocus
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com UK
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com India
Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus
Cellectar Biosciences Trading Halted: News Pending - AInvest
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):